AVGN Avigen, Inc. featured news, full reports, and detailed charts
Avigen, Inc. (AVGN) Wrap Up:
Avigen is a biopharmaceutical company focused on developing and commercializing small molecule therapeutics to treat serious neurological and neuromuscular disorders. Our current lead product candidates primarily address spasticity and neuromuscular spasm and neuropathic pain. Our goal is to retain rights to commercialize our products in North America and therefore we expect, when appropriate, to build a sales and marketing infrastructure. We intend to seek to out-license rights to develop and market our products outside the United States. We also intend to continue to look for opportunities to expand our pipeline of compounds through a combination of internal research, acquisitions, and in-licensing as appropriate. Avigen, Inc. is a Delaware corporation that was incorporated on October 22, 1992 and is based in the San Francisco Bay Area. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f17%2f0001206774-08-000531.html#FIS_BUSINESS"Avigen Inc. (AVGN:NASDAQ)
Snapshot of Avigen Inc. (AVGN)
|
OPEN
$1.42
|
PREVIOUS CLOSE
$1.44
|
|
|
DAY HIGH
$1.54
|
DAY LOW
$1.42
|
|
|
52 WEEK HIGH
10/15/09 - $1.64
|
52 WEEK LOW
12/15/08 - $0.49
|
|
|
MARKET CAP
42.4M
|
AVERAGE VOLUME 3 mo
16.9K
|
|
|
DILUTED EPS TTM
$-0.37
|
SHARES OUTSTANDING
29.8M
|
|
|
AVGN Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
AVGN Top Compensated Officers
Executives, Board Directors
Key developments for Avigen Inc. (AVGN)
Avigen Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2009. For the quarter, the company reported a net loss of $1.3 million, or $0.04 per share, compared to $7.3 million, or $0.25 per share, for the quarter ended June 30, 2008. Revenue was $0.10 million. Net interest income and other income were $347,000 and $703,000 for the quarters ended June 30, 2009 and 2008, respectively. This decrease primarily reflects the lower outstanding balances of interest-bearing cash and securities, as well as a general decline in market interest rates that have led to a lower average yield earned on Avigen's portfolio. For the quarter, the company reported loss from operations of $1,898,000 compared with $8,162,000for the same period a year ago. For the six months ended June 30, 2009, the company reported a net loss of $8.5 million, or $0.29 per share, compared to $14.8 million, or $0.50 per share, for the quarter ended June 30, 2008. Revenue was $0.10 million. Net interest income and other expenses were $771,000 for the six months ended June 30, 2009 compared to $1.5 million for the same period in 2008. For the six months, the company reported loss from operations of $9,654,000 compared with $16,439,000for the same period a year ago.
Avigen Inc. reported earnings results for the first quarter ended March 31, 2009. For the quarter, the company reported a net loss of $7.2 million, or $0.24 per basic and diluted share, for the quarter ended March 31, 2009, compared to a net loss of $7.4 million, or $0.25 per basic and diluted share, for the quarter ended March 31, 2008. Loss from operations for the quarter was $7.8 million compared to $8.3 million for the same period last year.
Avigen Inc. announced that special meeting of stockholders held on March 27, 2009, to amend company's bylaws to permit stockholders to elect directors to the Board of Directors.
AVGN Competitors
| Company | Last | Change |
| VaxGen Inc | $0.62 USD | +0.01 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | AVGN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 5.9x |
|
| Price/Book | 1.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.0x |
|
|
AVGN |
||
AVGN transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
